Efficacy & Safety of Baricitinib in Sjogren's Syndrome

Status Active, not recruiting

Clinical Trial Summary

The investigators had observed that baricitinib was effective and safe in active pSS patients in a pilot study. So the investigators plan to conduct a multi-center, prospective, open-label, randomized study to compare the efficacy of baricitinib + hydroxychloroquine (HCQ) with HCQ alone in active pSS patients. The participants will be randomized (1:2) to receive HCQ (200mg twice a day) or baricitinib (4mg per day) + HCQ (200mg twice a day) until week 24. The primary endpoint is the ESSDAI and ESSPRI response (define as an improvement of ESSDAI at least three points, and ESSPRI at least one point or 15%) at 12 weeks. According to an expected response rate of 70% in baricitinib + HCQ group and 30% in HCQ group, the investigators will involve approximately 87 participants (29:58) with 20% drop out rate. The investigators will switch HCQ to baricitinib + HCQ if the participants has no response at 12 weeks. The investigators hypothesized that baricitinib was effective and safe in active pSS patients.

Clinical Trial Description

All participants will be divided into HCQ group or HCQ + baricitinib group randomly. On the basis of the HCQ treatment before, the participants in the latter group will be given baricitinib 4mg once a day. The participants will come to visit at week 0, 4, 8, 12, 16, 20 and 24. The final evaluation will be at week 24. The participants who has no response to HCQ treatment alone at week 12 will be switched to baricitinib + HCQ group and treated with baricitinib 4mg per day until the end of the study (week 24). Baseline information included demographics, SS duration, clinical manifestations, laboratory parameters, current medications, and disease activity. Laboratory tests, including complete blood counts, urinalysis, liver and renal function tests, ESR, and IgG test were performed at each visit. Disease activity was assessed using the ESSDAI, EULAR primary SS patient reported index (ESSPRI), and physician global assessment (PGA) scores. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05016297
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 14, 2022
Completion date	November 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Completed	`NCT04968912` - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)	Phase 2
Completed	`NCT03203382` - Corneal Nerve Structure in Sjogren's
Completed	`NCT00809003` - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease	N/A
Completed	`NCT00023491` - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells	N/A
Completed	`NCT05005806` - Fish Oil (Omega 3 ) in Sjogren's Syndrome	Phase 2/Phase 3
Enrolling by invitation	`NCT03436576` - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye	Phase 3
Terminated	`NCT04143841` - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease	N/A
Completed	`NCT03611283` - Topical Management of Xerostomia With Dry Mouth Products	N/A
Recruiting	`NCT06104124` - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity	Phase 3
Recruiting	`NCT05115487` - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting	`NCT06437652` - An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Recruiting	`NCT05383677` - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome	Phase 2
Not yet recruiting	`NCT03938207` - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed	`NCT04546542` - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Recruiting	`NCT05085431` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome	Early Phase 1
Completed	`NCT00565526` - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed	`NCT01369589` - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness	Phase 1/Phase 2
Completed	`NCT00001953` - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of Baricitinib in Sjogren's Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms